

15 January 2019

ALS appoints international based Non-Executive Director

ALS Limited (ASX: ALQ) announces the appointment of Siddhartha Kadia, Ph.D. as an independent Non-Executive Director effective immediately.

ALS Chairman Bruce Phillips welcomed Dr Kadia, who is based in San Diego, to the ALS Limited Board, commenting that his broad international experience, creative insight, technical skills and expertise in the Life Sciences sector were complementary to the ALS Board.

“We are particularly pleased to have a person with Siddhartha’s diverse international business experience join the Board at a time when ALS is continuing to expand its strategic focus and direction globally.

Mr Kadia was formerly President and CEO of EAG Laboratories located in San Diego. He has also been a Director of USA listed companies Newport Corporation (NSDQ:NEWP) and Volcano Corporation (NSDQ:VOLC)

Mr Kadia’s professional background is detailed in the following attachment.

-ENDS-

Further information:

Bruce Phillips
Chairman
ALS Limited
+61 (7) 3367 7900

About ALS Limited

ALS is a global Testing, Inspection & Certification business. The company's strategy is to broaden its exposure into new sectors and geographies where it can take a leadership position.



Siddhartha Kadia: Professional Background

Dr. Siddhartha Kadia has a background in executive management and public company governance in a range of global businesses, predominantly in the Life Sciences and TIC (Testing, Inspection and Certification) industries.

He has a wealth of international expertise in global markets with an emphasis on North America, Asia and Europe. His areas of expertise include CEO level executive leadership, corporate strategy, M&A, laboratory operations, global marketing and e-business.

Dr Kadia was formerly President and CEO of EAG Laboratories located in San Diego, which was acquired by Eurofin Scientific in 2017 and he continued to serve as the CEO of EAG laboratories until December 2018.

Prior to EAG, he served in various executive roles with Life Technologies Corporation, including President Life Sciences; President Greater China region; President Japan; and Chief Marketing Officer. Dr Kadia also worked with McKinsey and company as a management consultant.

More recently Dr Kadia has served on the Board of Directors of Newport Corporation, a leading global supplier of advanced technology products and solutions for scientific research, life and health science, aerospace and defence, photovoltaics, industrial manufacturing, semiconductors and microelectronics markets. Newport became part of MKS Industries in April 2016. Mr Kadia also previously served on the Board of Directors of Volcano Corporation, a medical technology company.

Dr Kadia was a post-doctoral fellow at John Hopkins University School of Medicine, Baltimore where he conducted research in neuroscience. He obtained his Ph.D. in biomedical engineering from Johns Hopkins University where he was awarded the David Israel Macht Award for Excellence in Research. He also holds a M.S. in biomedical engineering from Rutgers University, New Jersey, and a B.E in electronics and telecommunications from Gujarat University in India.

-ENDS-